logo
Sign In
| Cerebrovascular accident

Praluent vs Vascepa

Side-by-side clinical, coverage, and cost comparison for cerebrovascular accident.
Deep comparison between: Praluent vs Vascepa with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.
Safety signalsVascepa has a higher rate of injection site reactions vs Praluent based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vascepa but not Praluent, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Praluent
Vascepa
At A Glance
RouteSC injection
FrequencyEvery 2-4 weeks
ClassPCSK9 inhibitor
RouteOral
FrequencyTwice daily
ClassOmega-3 fatty acid
Indications
  • Myocardial Infarction
  • Coronary heart disease
  • Cerebrovascular accident
  • Angina, Unstable
  • Hypercholesterolemia
  • Familial hypercholesterolemia - heterozygous
  • Homozygous Familial Hypercholesterolemia
  • Myocardial Infarction
  • Cerebrovascular accident
  • Angina, Unstable
  • Hypertriglyceridemia
Dosing
Hypercholesterolemia, Myocardial Infarction, Coronary heart disease, Cerebrovascular accident, Angina, Unstable 75 mg SC once every 2 weeks or 300 mg SC once every 4 weeks; may adjust to 150 mg SC every 2 weeks if LDL-C response is inadequate.
Familial hypercholesterolemia - heterozygous (adults on LDL apheresis), Homozygous Familial Hypercholesterolemia 150 mg SC once every 2 weeks; may be administered without regard to timing of LDL apheresis.
Familial hypercholesterolemia - heterozygous (pediatric, <50 kg) 150 mg SC once every 4 weeks; may adjust to 75 mg SC once every 2 weeks if LDL-C response is inadequate.
Familial hypercholesterolemia - heterozygous (pediatric, >=50 kg) 300 mg SC once every 4 weeks; may adjust to 150 mg SC once every 2 weeks if LDL-C response is inadequate.
Myocardial Infarction, Cerebrovascular accident, Angina, Unstable 4 grams per day (four 0.5 gram capsules twice daily with food or two 1 gram capsules twice daily with food) as adjunct to maximally tolerated statin therapy.
Hypertriglyceridemia 4 grams per day (four 0.5 gram capsules twice daily with food or two 1 gram capsules twice daily with food) as adjunct to diet.
Contraindications
  • Previous serious hypersensitivity reaction to alirocumab or any excipient in PRALUENT
  • Known hypersensitivity (e.g., anaphylactic reaction) to icosapent ethyl or any of its components
Drug Interactions
163View drug interactions
230View drug interactions
Adverse Reactions
Most common (>=2%) Injection site reactions, influenza, diarrhea, myalgia, muscle spasms, contusion
Serious Hypersensitivity vasculitis, nummular eczema, angioedema
Postmarketing Angioedema, influenza-like illness
Most common (>=3%) musculoskeletal pain, peripheral edema, constipation, gout, atrial fibrillation
Postmarketing diarrhea, blood triglycerides increased, abdominal discomfort, pain in the extremities
Pharmacology
Alirocumab is a human monoclonal antibody that inhibits PCSK9, a protein that promotes LDL receptor degradation on hepatocytes, thereby increasing LDL receptor availability and lowering circulating LDL-C levels.
Icosapent ethyl (EPA ethyl ester) reduces hepatic VLDL-TG synthesis and/or secretion and enhances TG clearance from circulating VLDL particles, with multi-factorial mechanisms likely contributing to cardiovascular risk reduction.
View Full FDA Information
View full FDA information
View full FDA information
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Praluent
  • Covered on 5 commercial plans
  • PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
View full coverage details ›
Vascepa
  • Covered on 5 commercial plans
  • PA (10/12) · Step Therapy (3/12) · Qty limit (9/12)
View full coverage details ›
UnitedHealthcare
Praluent
  • Covered on 4 commercial plans
  • PA (1/8) · Step Therapy (1/8) · Qty limit (1/8)
View full coverage details ›
Vascepa
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
View full coverage details ›
Humana
Praluent
  • Covered on 0 commercial plans
  • PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
View full coverage details ›
Vascepa
  • Covered on 0 commercial plans
  • PA (1/3) · Step Therapy (0/3) · Qty limit (2/3)
View full coverage details ›
Coverage data sourced from MMIT. Updated monthly.
Savings
$50/momo
MyPraluent Copay Card
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Vascepa.
Compare Other Drugs
Prior Authorization
Let us handle your prior authsJust enter your patient's info and we'll:
  • Verify eligibility with the payer.
  • Pull the right PA forms directly from the payer.
  • Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Free to start · HIPAA compliant
Next Steps for Your Patient
PraluentView full Praluent profile
VascepaView full Vascepa profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.
Cibinqo vs. DupixentSaxenda vs. WegovySkyrizi vs. StelaraCosentyx vs. TaltzTosymra vs. EmgalityAjovy vs. Nurtec ODTXarelto vs. EliquisOpdivo vs. KeytrudaKisqali vs. IbranceXtandi vs. ErleadaPraluent vs. RepathaCibinqo vs. OpzeluraIlumya vs. TaltzKisunla vs. LeqembiView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsA-Z IndicationsCompare Drugs
CompanyAboutCareersContact UsSecurity
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.